Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941907 | 0.75 | PPARG (0.53) | KIF11PPARGPPARAPTGESALOX5 | |
| SCHEMBL4633669 | 0.73 | KIF11 (0.42) | KIF11SLC6A1SLC6A11PPARGPPARA | |
| SCHEMBL7048548 | 0.73 | KIF11 (0.48) | KIF11SLC6A1SLC6A11PPARGPPARA | |
| SCHEMBL27433687 | 0.72 | PPARG (0.47) | KIF11PPARGPPARAPTGESALOX5 | |
| SCHEMBL16197752 | 0.72 | KIF11 (0.50) | KIF11SLC6A1SLC6A11 | |
| SCHEMBL4633668 | 0.72 | PPARA (0.45) | SLC6A1SLC6A11PPARGPPARAPPARD | |
| SCHEMBL1564807 | 0.71 | PPARA (0.59) | PPARGPPARAPTGESALOX5TAS1R3 | |
| SCHEMBL18349848 | 0.70 | TK1 (0.43) | KIF11SLC6A1SLC6A11TK1 | |
| SCHEMBL29119224 | 0.69 | F7 (0.43) | PPARGPPARAPPARDTDP1 | |
| SCHEMBL3997642 | 0.69 | KIF11 (0.46) | KIF11SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171849-A1 | Deprotecting peptide from allyl-type protecting groups by palladium catalysis in presence of allyl acceptor; lactamization; solid phase synthesis | LONZA AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1794180-B1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1794180-A1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032457-A9 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006032457-A1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-5777077-A | SINGLE PHASE LIQUID SOLUTION OF A SOLUBLE ORGANOPALLADIUM COMPLEX CATALYST, A CARBOXYLIC ACID AND AN ACCEPTOR E.G. DIMEDONE, N-METHYLANILINE, N,N'-DIMETHYLBARBITURIC ACID, MORPHOLINE OR N-METHYLMORPHOLINE; SIDE EFFECT REDUCTION | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171849-A1 | Deprotecting peptide from allyl-type protecting groups by palladium catalysis in presence of allyl acceptor; lactamization; solid phase synthesis | PEPD, VIP, DNPEP | KIF11 4284/4885SLC6A1 2876/4885SLC6A11 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.